Filgrastim in Patients with Neutropenia
Filgrastim in Patients with Neutropenia
复制标题
非格司亭治疗中性粒细胞减少症患者
作者：
G. Lyman;N. Kuderer
与治疗和疾病相关的中性粒细胞减少症与一系列负面临床效应有关，如发热性中性粒细胞减少症、有记录的感染、因感染相关的发病率住院、感染相关的死亡率以及按计划实施化疗剂量的能力下降。减少或推迟剂量可能会降低应答率，从而危及治疗的有效性。不仅会对临床结果产生不利影响，而且这些并发症也会对患者的生活质量产生负面影响。非格列辛是一种造血生长因子，主要作用于刺激中性粒细胞的增殖和分化。非格列辛能够减少癌症或HIV感染患者中性粒细胞减少症的发生率和严重程度，以及伴随而来的并发症。虽然很少有数据评估粒细胞集落刺激因子治疗对生活质量的影响，但人们认为，通过减少与治疗相关的并发症和增强长期疾病控制的潜力，可以看到好处。一种新的、长效的非格列格辛现在已经上市，它有可能通过减少必要的注射次数来简化中性粒细胞减少症的管理，并进一步提高患者的生活质量。需要更多包含生活质量问题作为终点的前瞻性对照试验。
Treatment- and disease-related neutropenia are associated with a number of negative clinical effects such as febrile neutropenia, documented infection, hospitalisation for infection-related morbidity, infection-related mortality, and decreased ability to administer the planned chemotherapy dose on schedule. Reductions or delays in dosage have the ability to jeopardise the effectiveness of treatment by lowering response rates. Not only are clinical outcomes adversely affected, but these complications can have a negative influence on patient quality of life. Filgrastim is a haematopoietic growth factor that primarily acts to stimulate the proliferation and differentiation of neutrophil progenitor cells. Filgrastim is capable of reducing the incidence and severity of neutropenia and the complications that accompany it in patients with cancer or HIV infection. Although there are few data evaluating the effect of treatment with granulocyte colony-stimulating factor on quality of life, it is assumed that the benefits would be seen through both the reduction of treatment-related complications and the enhanced potential for long-term disease control. A new, longer-acting form of filgrastim is now available that has the potential to simplify the management of neutropenia and further improve patient quality of life by decreasing the number of necessary injections. Additional prospective controlled trials that contain quality-of-life issues as endpoints are needed.
影响因子：
20.3
作者：
Godwin, JE;Kopecky, KJ;Appelbaum, FR
通讯作者：
Appelbaum, FR
一项在成人急性淋巴细胞白血病缓解诱导和巩固化疗期间使用非格司亭的随机对照试验：CALGB 研究 9111。
影响因子：
20.3
作者：
Larson,RA;Dodge,RK;Linker,CA;Stone,RM;Powell,BL;Lee,EJ;Schulman,P;Davey,FR;Frankel,SR;Bloomfield,CD;George,SL;Schiffer,CA
通讯作者：
Schiffer,CA
大鼠中正常和 2A 型冯维勒布兰德因子的清除率。
影响因子：
20.3
作者：
StoddartJr,JH;Andersen,J;Lynch,DC
通讯作者：
Lynch,DC